6%. This reflects outperformance of both the industry and the market. The ROA has exhibited similar outperformance of both industry and market. The return on assets for JNJ over the past several years has ranged from 13.1% in 2007 to 17.l% in 2005. The industry five-year average is 8.85% and the market five-year average is 7.50%.
SWOT Analysis
Strengths
Net Income increased despite decline in revenues
Growth in each business segment
R&D expense growing slower than revenues
2-year upward trend in net income
Upward trend in cash levels
Upward trend in cash flow from operations
Current ratio 46.36% higher than industry
Interest coverage 80.09% higher than industry
Net margin 14.04% higher than industry
Return on Equity 1414.79% higher than industry
Return on Assets 48.02% higher than industry
Weaknesses
Decline in revenue this year (1st time in 75 years)
Cost of revenue increasing faster than revenue
SGA expense increasing faster than revenue
Incurred income expense for the first time in years
Increase in LT debt
Increase in overall leverage
P/E 10.19% lower than industry
Quick ratio 27.7% lower than industry
Debt-to-equity ratio 160% higher than industry
Gross margin 0.2% lower than industry
Opportunities
Further absorption of PCH can reduce costs
Strong emerging market performance
Geographic expansion of major consumer product lines
New pharmaceutical products, especially in HIV (PRESTIZA, ustekinumab)
7-10 new SEC filings in next 2 years
New MD&D products (REALIZE, ANIMAS insulin pump)
2.8 trillion in untapped health care market segments
Threats
Need for FDA approval for new drugs
Strong competition in most segments
Economic downturn hurts core U.S. market
Economic downturn stunts growth in lucrative emerging markets (especially BRIC)
Dependent on aging population for continued growth
Overall, Johnson & Johnson is a strong company. Their finances are stable and the company has demonstrated that they are able to identify and improve upon areas of financial weakness, such as the recent decline in cash holdings. They are a well-diversified firm, which allows them to weather weakness in any one segment. This does leave them exposed to broader economic downturns, and in 2008 they appear poised to post their first year of declining revenues in 75 years. However profits and cash flow from operations both grew in 2008 despite this. They are an industry leader and there is far more cause for optimism than pessimism given their current financial position. Their low P/E ratio is more indicative of an opportunity to buy than any long-term fundamental weaknesses in their financial statements or their market performance.
Recommendations
The current challenges facing Johnson & Johnson are largely based on struggles in the global economy. JNJ is very well-diversified, but further improvement of diversification will help them to kick start growth in the face of a slowing economy. To that end, the first recommendation is to increase their presence in emerging markets. While some markets are subject to the same slowdown facing the U.S., others such as Russia and Brazil are more insulated. The Chinese and Indian economies are hurting relative to their recent successes but again there are long-term opportunities in each of those nations. JNJ should expand into these countries to gain a measure of economic diversification.
The second recommendation is that Johnson & Johnson should increase research and development expenditures. This will allow them to move into new markets within their core health care and consumer product fields. More importantly it will allow them to have a multitude of quality drugs in the development pipeline when the economy begins to improve and the baby boomers are still in their prime health care spending years. After a couple of years of stabilized R&D expenses and faced with sharply declining sales in core products now subject to competition from generics, the time has come for JNJ to renew its commitment to new product development.
The third recommendation is that Johnson & Johnson should tap into the $2.8 trillion in health care segments in which they do not presently compete. They have strong advantages in terms of cost, brand and distribution that can enable them to be a formidable competitor in any medical product business they enter. They can achieve growth in the face of a slowing economy by expanding the breadth of their product offerings. They can take advantage of rock bottom equity prices and their strong cash position to purchase companies that will help them enter these new markets.
The fourth recommendation is that Johnson & Johnson should continue to pursue the most efficient capital structure. This means that they should continue to take advantage of their low multiple to buy back stock, and that they should increase their debt level. They have ample ability to cover an increased debt load and can be expected to have a very low cost of debt at current interest rate levels.
A fifth recommendation is that JNJ should seek to contain its cost of revenues. This has, in general, been increasing at a faster rate than have revenues. While overall JNJ's gross margin is in line with past performance and with its performance in relation to the market, the company should take the approach that by being a leader in gross margin, they can increase their profits at a faster rate. Every 0.1% improvement on their gross margin is worth $80 million, so this is an area where JNJ can improve the bottom line rapidly.
The final recommendation is that JNJ should contain the growth in its Selling, General and Administration expense. This has been increasing more rapidly than sales in the past couple of years, which is cause for concern. In tougher economic times, the company should hold the line on this type of expenses and plow their money into more productive areas, such as R&D.
Works Cited
Financial Statements and Ratios from MSN Moneycentral. Retrieved January 27, 2009 at http://moneycentral.msn.com/investor/invsub/results/compare.asp?Symbol=U.S.%3aJNJand http://moneycentral.msn.com/investor/invsub/results/statemnt.aspx?symbol=JNJ
Johnson & Johnson 2007 Annual Report. Retrieved January 27, 2009 at http://files.shareholder.com/downloads/JNJ/531891617x0x171267/057640F8-B2C0-4B0F-9F54-7A24A553C3CE/2007AR.pdf
Ratios also from Reuters. Retrieved January 27, 2009 at http://www.reuters.com/finance/stocks/ratios?symbol=JNJ.N
Associated Press (2009). Profit Rises but Johnson & Johnson Expects a Weak Year. New York Times. Retrieved January 27, 2009 at http://www.nytimes.com/2009/01/21/business/21drug.html?ref=business
Annual Income Statement
Annual
Interim
In Millions of U.S. Dollars except for per share items)
Period Length
12 Months
Restated
Period Length
12 Months
Revenue
Other Revenue, Total
Total Revenue
Cost of Revenue, Total
Gross Profit
Selling/General/Admin. Expenses, Total
Research & Development
Depreciation/Amortization
Interest Expense, Net - Operating
Interest/Investment...
Executive Stock Option Plans "If the company does not do better than its competitors, but the stock market goes up, executives do very well from their stock options. This makes no sense." Discuss viewpoint. Can you think of alternatives to the usual executive option plan that take the viewpoint into account? Executive stock options are performance-based incentive plans that became popular in the 1950s and 1960s. They declined due to the stock
Works CitedOur semester plans gives you unlimited, unrestricted access to our entire library of resources —writing tools, guides, example essays, tutorials, class notes, and more.
Get Started Now